User profiles for Mark J Ratain
Mark RatainLeon O. Jacobson Professor of Medicine, The University of Chicago Verified email at uchicago.edu Cited by 47945 |
Tumour heterogeneity in the clinic
Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …
genotype variations between patients, called interpatient heterogeneity, that predict the …
Oral chemotherapy: rationale and future directions.
MD DeMario, MJ Ratain - Journal of clinical oncology, 1998 - ascopubs.org
PURPOSE AND METHODS The expanding role of oral chemotherapy in oncology is
suggested by the abundance of orally formulated agents currently in development. The …
suggested by the abundance of orally formulated agents currently in development. The …
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents
…, M Koehler, R Parchment, MJ Ratain… - Clinical cancer …, 2010 - AACR
The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) charged
the Biomarker Task Force to develop recommendations to improve the decisions about …
the Biomarker Task Force to develop recommendations to improve the decisions about …
[HTML][HTML] Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
…, SM Shreeve, MJ Ratain, J Settleman… - … England Journal of …, 2010 - Mass Medical Soc
Background Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK)
are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such …
are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such …
[PDF][PDF] Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
MJ Ratain, TIM Eisen, WM Stadler… - Journal of Clinical …, 2006 - biostat.wisc.edu
… Address reprint requests to Mark J. Ratain, MD, University of Chicago, 5841 S Maryland
Ave, MC2115, … The results of this placebo-controlled phase II study clearly demonstrate that …
Ave, MC2115, … The results of this placebo-controlled phase II study clearly demonstrate that …
Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
Purpose Severe toxicity is commonly observed in cancer patients receiving irinotecan. UDP-glucuronosyltransferase
1A1 (UGT1A1) catalyzes the glucuronidation of the active …
1A1 (UGT1A1) catalyzes the glucuronidation of the active …
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active …
…, TR Tephly, BL Coffman, MJ Ratain - The Journal of …, 1998 - Am Soc Clin Investig
Irinotecan (CPT-11) is a promising antitumor agent, recently approved for use in patients
with metastatic colorectal cancer. Its active metabolite, SN-38, is glucuronidated by hepatic …
with metastatic colorectal cancer. Its active metabolite, SN-38, is glucuronidated by hepatic …
Measuring financial toxicity as a clinically relevant patient‐reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)
…, LH Nicholas, JM O'Connor, B Brockstein, MJ Ratain… - Cancer, 2017 - Wiley Online Library
BACKGROUND Cancer and its treatment lead to increased financial distress for patients. To
the authors' knowledge, to date, no standardized patient‐reported outcome measure has …
the authors' knowledge, to date, no standardized patient‐reported outcome measure has …
[HTML][HTML] Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth
factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive …
factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive …
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea
…, TM Lestingi, R Mick, J Ramirez, EE Vokes, MJ Ratain - Cancer research, 1994 - AACR
Irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11) is
hydrolyzed by the enzyme carboxyl esterase to 7-ethyl-10-hydroxycamptothecin (SN-38), …
hydrolyzed by the enzyme carboxyl esterase to 7-ethyl-10-hydroxycamptothecin (SN-38), …